Use of water soluble extracts from ulva sp. by probiotics and fish bacterial pathogens

BACKGROUNDS The potential of seaweeds as dietary components is considered for a wide range of cultured fish species. In this context, Ulva is investigated as a good source of protein, minerals and vitamins. In addition, of probiotics are used to improve fish growth and modulate immune system and intestinal microbiota. To promote probiotics colonization and maintenance in the intestine, prebiotics are included in fish diets. Prebiotics are indigestible substrates used as energy sources for gastrointestinal microbiota, with a positive effect on the nutrition and health status of the host. In the present work, ability of selected probiotic and fish pathogen strains to use water soluble extracts from Ulva as nutrient source has been evaluated. MATERIALS AND METHODS Water-soluble extracts from Ulva sp. prepared by sonication of dehydrated samples were used to supplement minimum medium (M9). Probiotics and pathogens growth was evaluated based on the optical densities measured with a microplate reader. RESULTS AND CONCLUSIONS Probiotics were able to grow in minimum medium using water soluble extracts as nutrient source. On the other hand, P. damselae subsp. piscicida and V. harveyistrains were also able to grow with Ulvaextracts as nutrient source. However, incubation time to reach maximum growth was longer. Although Ulva extract may support growth of both probiotics and pathogen bacteria, faster growth of probiotics may help for the establishment of probiotic populations in the intestinal environment. In addition, beneficial effects on growth performance, gut microbiota, immunity and disease resistance of Ulva for Solea senegalensisare being studied. This work was funded by INIA, Ministerio de Economía y Competitividad and FEDER (RTA201400023 C0202).This work was funded by INIA, Ministerio de Economía y Competitividad and FEDER (RTA201400023 C0202).Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry

Background and Aims: Drug-induced liver injury (DILI) presents with a wide phenotypic spectrum requiring an extensive differential diagnosis. Hepatitis E virus (HEV) is not systematically ruled out during acute hepatitis assessment in Spain. The aims of this study were to establish the role of HEV infection and its phenotypic presentation in patients initially suspected of DILI and to determine the anti-HEV seroprevalence rate. Methods: An analysis of 265 patients with suspected DILI and considered for enrolment in the Spanish DILI Registry and 108 controls with normal liver profiles was undertaken. Anti-HEV Immunoglobulin (Ig) G antibodies were analyzed in serum from all subjects. In those with serum samples extracted within 6 months from liver damage onset (n=144), HEV antigen (Ag) and anti- HEV IgM antibodies were tested in duplicate by ELISA. In addition, RT-PCR was performed externally in 8 patients. Results: Out of 144 patients, 12 (8%) were positive for anti-HEV IgM, mean age 61 years. Underlying hepatic diseases (OR=23.4, p20 folds upper limit of normal (OR=10.9, p=0.002) were associated with the diagnosis of acute hepatitis E. The overall anti-HEV IgG seroprevalence rate was 35%, evenly distributed between patients with suspected DILI (34%), and controls (39%). Conclusions: HEV seroprevalence and acute hepatitis E rates are relatively high in Spain. A search for active HEV infection is therefore advised in patients assessed for suspicion of DILI, particularly in patients with underlying liver diseases and high transaminase levels.The present study has been supported by grants of the Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional FEDER (contract numbers: FIS PI0274-2016, PI-0285- 2016, PI 18-01804, PI 18-00901, PT17/0017/0020, CM17/00243, JR16/00015, B-0002-2019, UMA-18-FEDERJA-193 and by the Agencia Española del Medicamento. SCReN and CIBERehd are funded by Instituto de Salud Carlos III. European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, IMI2-Translational Safety Biomarker Pipeline (TransBioLine). The funding sources had no involvement in the study design, in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the manuscript for publicatio